In this week’s View, Dr. Eagle discusses trends in the use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, then looks at a collaborative meta-analysis of large placebo-controlled trials that examines the impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes. Finally, Dr. Eagle explores insights from the PEGASUS-TIMI 54 trial regarding patient selection for long-term secondary prevention with ticagrelor. 

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Dyslipidemia, Heart Failure and Cardiomyopathies, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Acute Heart Failure, Prevention, Valvular Heart Disease

Keywords: Atrial Fibrillation, Warfarin, Anticoagulants, Stroke, Anemia, Sodium-Glucose Transporter 2 Inhibitors, Sodium-Glucose Transporter 2, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Glomerular Filtration Rate, Renal Insufficiency, Chronic, Kidney Failure, Chronic, Heart Failure, Heart Disease Risk Factors, Glucose, Kidney, EaglesEyeView, Ticagrelor, Patient Selection, Myocardial Infarction, Gastrointestinal Hemorrhage

< Back to Listings